Role of Biologics in Driving Spinal Fusion Market Growth
Biologics are becoming a cornerstone of spinal fusion procedures, playing a critical role in ensuring faster healing and long-term success. MRFR’s Spinal Fusion Market highlights the increasing use of bone grafts, growth factors, and synthetic substitutes that enhance the fusion process.
Traditionally, autografts were the gold standard for spinal fusion. However, limitations such as donor site morbidity and limited availability have encouraged the adoption of advanced biologics. Synthetic graft substitutes and demineralized bone matrices are now widely used alternatives, offering effective outcomes with fewer complications.
Bone morphogenetic proteins (BMPs) have gained particular attention due to their ability to stimulate new bone growth and accelerate recovery. Their application is revolutionizing the way surgeons approach complex spinal procedures.
The role of biologics is not limited to healing; they are also instrumental in reducing revision surgery rates. This dual benefit makes them an increasingly vital component of the modern Spinal Fusion Market. With ongoing R&D, biologics are expected to further strengthen the growth prospects of this market globally.